7,693 reports of this reaction
2.3% of all CLOPIDOGREL reports
#6 most reported adverse reaction
DIZZINESS is the #6 most commonly reported adverse reaction for CLOPIDOGREL, manufactured by Sanofi-Aventis U.S. LLC. There are 7,693 FDA adverse event reports linking CLOPIDOGREL to DIZZINESS. This represents approximately 2.3% of all 332,980 adverse event reports for this drug.
Patients taking CLOPIDOGREL who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for CLOPIDOGREL, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for CLOPIDOGREL:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 7,693 FDA reports for CLOPIDOGREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.3% of all adverse event reports for CLOPIDOGREL, making it a notable side effect.
If you experience dizziness while taking CLOPIDOGREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.